Korsana Biosciences emerged from stealth on February 18, 2026, with $175 million in funding to develop KRSA-028, a next-generation antibody targeting amyloid beta for Alzheimer's treatment 3 4 KRSA-028 was discovered in partnership with Paragon Therapeutics and utilizes the proprietary THETA platform, which uses transferrin receptor 1 (TfR1) engineering to enable brain penetration 1 4 The antibody is engineered as a subcutaneous injection rather than intravenous infusion to improve treatment convenience and reduce adverse effects like amyloid-related imaging abnormalities (ARIA) 1 Korsana plans to initiate clinical trials in early 2027, with initial safety data expected in mid-2027 and proof-of-concept amyloid plaque clearance data by end of 2027 3 Korsana represents the seventh biotech launch from assets developed by Paragon Therapeutics, which acts as a hub-and-spoke model creating focused spinout companies 1 Sources: 1. https://www.biopharmatrend.com/news/new-neurode...
- Get link
- X
- Other Apps